Shots:
BI has licensed a pre-clinical small molecule program from Kyowa Kirin to develop it as a potential treatment for autoimmune diseases
As per the deal, BI will receive exclusive rights to develop the small molecule program globally, expanding BI’s inflammatory pipeline
In contrast, Kyowa Kirin will receive up to €640M (~$744.4M), incl. an upfront payment, development,…
